Skip to main content
Diagnostic and Interventional Radiology logoLink to Diagnostic and Interventional Radiology
. 2026 Sep 1;32(5):709–714. doi: 10.4274/dir.2025.253499

Post-cryoablation magnetic resonance imaging features of desmoid tumors: a pictorial essay

Leonor G Savarese 1,✉, Nicolas Papalexis 2, Marco Miceli 2, Michela Carta 2, Giancarlo Facchini 2
PMCID: PMC13530442  PMID: 41357250

ABSTRACT

Desmoid tumors (DTs) are rare, locally aggressive soft tissue neoplasms with highly variable clinical behavior. Although benign, their infiltrative nature can lead to considerable morbidity. DTs present a major challenge due to their unpredictable behavior and potential for misdiagnosis. Recently, there has been a large shift in the treatment strategy for DTs, and the number of cases being followed up with imaging has increased. Cryoablation has emerged as a minimally invasive treatment option, yet post-procedural imaging features remain poorly characterized. This study illustrates the magnetic resonance imaging (MRI) evolution of DTs following percutaneous cryoablation, emphasizing key patterns across pre-treatment, intra-procedural, and follow-up studies. The available MRI follow-up ranged from 6 to 30 months. Through a pictorial approach, we aimed to provide radiologists with practical insights to avoid misinterpretation of expected post-treatment changes as recurrence and to improve clinical management.

Keywords: Desmoid tumor, magnetic resonance imaging, follow-up studies, soft tissue neoplasm, ablation technique, cryoablation, radiology, interventional


Main points

• Magnetic resonance imaging (MRI) is fundamental in the post-cryoablation follow-up of desmoid tumors, enabling precise differentiation between expected treatment-related changes and tumor recurrence.

• Key imaging findings after cryoablation include a central non-enhancing cavity, peripheral granulation tissue with contrast enhancement, and progressive fibrosis reflected by decreasing T2 signal intensity.

• Recognizing the temporal evolution of these MRI features is essential to avoid misinterpretation and to guide appropriate clinical decision-making.

Desmoid-type fibromatosis, also known as desmoid tumor (DT) or aggressive fibromatosis, is a rare, locally invasive fibroblastic proliferation characterized by an unpredictable clinical course.1, 2 These tumors account for < 3% of soft tissue neoplasms, with an incidence of approximately 3–5 cases per million annually. They typically affect individuals in their third to fourth decades of life and show a higher prevalence in women. Most cases are sporadic and arise in extra-abdominal locations, particularly the extremities and trunk.3

DTs pose a major diagnostic and management challenge due to their variable behavior, which can range from rapid growth to spontaneous regression. Recent guidelines emphasize an initial surveillance strategy to prevent overtreatment, reserving intervention for symptomatic or progressive cases. However, a decision to initiate therapy earlier may be considered when DTs are located near critical structures, as there may be a higher risk of morbidity before the disease stabilizes. When treatment is warranted, options include systemic therapies (such as chemotherapy or tyrosine kinase inhibitors) and local interventions.4, 5

Cryoablation has emerged as a promising local therapy and is now included in updated management guidelines. This minimally invasive technique employs cryoprobes to induce tumor cell death through extreme cold, achieved via the Joule–Thomson effect. Cellular destruction results from intracellular ice formation and vascular injury, leading to ischemia. Image-guided cryoablation, typically performed under computed tomography guidance, allows precise visualization of a low-attenuation ice ball in soft tissues, providing visual confirmation that the tumor is included in the cryoablated volume.6 Recent studies have shown that image-guided percutaneous cryoablation appears to be safe and effective for local control in patients with extra-abdominal DTs.7, 8, 9, 10, 11 In this pictorial essay, we illustrate six representative cases of extra-abdominal DTs treated with percutaneous cryoablation, including three men and three women (age range 33–54 years). Tumor sites comprise the gluteal region (n = 2), lumbar wall (n = 1), abdominal wall (n = 1), scapular region (n = 1), and calf (n = 1) (Table 1).

Table 1. Patients’ demographics and characteristics.

Case

Age (years)

Sex

Tumor location

Magnetic resonance imaging follow-up duration (months)

1

35

Male

Right gluteal region

18

2

54

Female

Right lumbar subcutaneous region

30

3

48

Female

Left abdominal wall

8

4

33

Male

Left gluteal subcutaneous region

25

5

50

Female

Left scapular region

18

6

33

Female

Calf

6

Role of magnetic resonance imaging

Magnetic resonance imaging (MRI) plays a critical role in the diagnosis, treatment planning, and follow-up of DTs. Imaging findings correlate with histopathologic features; hyperintense areas on T2-weighted and enhancing sequences reflect high cellularity, whereas hypointense, non-enhancing regions correspond to fibrous, low-cellularity components.12, 13 An increase in collagenization within the tumor is associated with a decrease in cellularity, suggesting a reduction in tumor activity. This can be seen on MRI as a decrease in enhancement and T2 hyperintensity, which are imaging features indicating a positive response to therapy.14

Post-cryoablation imaging findings

Post-cryoablation MRI findings evolve. In early follow-up, considerable edema may be noted in the cryoablation area and adjacent soft tissues (Figure 1). Early imaging signs after the procedure include a non-enhancing ablation cavity with a high T2 signal, corresponding to coagulative necrosis. A thin inner rim of low T2 signal, indicative of hemosiderin rim (hemorrhagic congestion), can be better visualized on T2 gradient echo sequences. A thicker outer rim of intermediate/low T2 signal with post-contrast enhancement corresponds to granulation tissue/vascular fibrosis (Figure 2).

Figure 1.

Figure 1

A 35-year-old man. Axial T2 fat-sat imaging (a) reveals a desmoid tumor in the right gluteal region (asterisk). A computed tomography scan taken during the procedure, axial (b) and reconstructed coronal (c) views, shows cryoprobes placed within the lesion, with the ice ball (yellow arrows) covering the entire tumor as well as a safety margin of healthy tissue. In the early follow-up, 1 week post-procedure, considerable edema was noted in the cryoablation area and adjacent soft tissues. A well-demarcated zone of edema (white arrows in d) that extends beyond the lesion’s margins, encompassing the gluteal muscles and the iliac bone, corresponds to the area covered by the ice ball. Note the thermoprotection of the skin, achieved by using sterile gloves filled with warmed saline and a subcutaneous injection of air (arrowheads in b, c).

Figure 2.

Figure 2

A 35-year-old man. Axial T2 fat-sat/short tau inversion recovery (STIR) (a-d) and post-contrast T1 fat-sat images(e-h) of a desmoid tumor in the right gluteal region, pre- and post-cryoablation, across different time frames (a, e: pre-treatment; b, f: 3 months; c, g: 9 months; d, h: 18 months). At the 3-month follow-up, a non-enhancing ablation cavity corresponding to the ablation cavity was observed (asterisk), displaying a markedly low signal on T2 fat-sat/STIR, suggestive of dense fibrosis, and surrounded by granulation tissue/vascular fibrosis with post-contrast enhancement (white arrows). The 9-month follow-up revealed a potential recurrence at the anterior margin of the ablation cavity, more clearly delineated on the post-contrast T1 fat-sat sequence as a nodular enhancing area (yellow arrow). By the 18-month follow-up, this enhancing nodular lesion had increased in size, extending to the medial and posterior margins, confirming the recurrence (yellow arrows).

In subsequent follow-ups, the non-enhancing ablation cavity shows a size reduction and may show a marked decrease in T2 signal intensity, indicative of dense fibrosis. Additionally, a progressive reduction in post-contrast enhancement of the outer rim of granulation tissue/vascular fibrosis can be noted (Figure 3). Finally, a reduction in lesion volume is expected in successful cases (Figure 4), with a progressive replacement by adipose tissue observed in subcutaneous cases (Figure 5). If tumor recurrence occurs, it can be observed on post-contrast sequences as a nodular enhancing area (Figure 2). Imaging findings are summarized in Table 2.

Figure 3.

Figure 3

A 54-year-old woman. Axial T2 fat-sat (a-e) and post-contrast T1 (f) and T1 fat-sat (g-j) imaging of a subcutaneous desmoid tumor in the right lumbar area, pre- and post-cryoablation, at different time frames (a, f: pre-treatment; b, g: 2 months; c, h: 7 months; d, i: 13 months; e, j: 30 months). In the 2 months post-procedure images, note a non-enhancing ablation cavity with high T2 signal at the lesion’s center, indicative of coagulative necrosis (asterisk). It is surrounded by an inner thin rim of low T2 signal (arrowheads) corresponding to a hemosiderin rim (hemorrhagic congestion) and an outer rim of high T2 signal and post-contrast enhancement (arrows) corresponding to granulation tissue/vascular fibrosis. In subsequent follow-ups, the non-enhancing ablation cavity exhibits a reduction in size and a marked decrease in T2 signal intensity, indicative of dense fibrosis. A progressive reduction in the post-contrast enhancement of the outer rim of granulation tissue/vascular fibrosis can also be seen.

Figure 4.

Figure 4

A 48-year-old woman. Axial T2 with fat-sat (a-c), axial T1 fat-sat post-contrast (d-f), and T2 gradient echo (g) of a left abdominal wall desmoid tumor, pre- and post-cryoablation, at different time frames (a, d: pre-treatment; b, e, g: 1 month; c, f: 8 months). In the images taken 1 month post-procedure, note a non-enhancing ablation cavity with high T2 signal corresponding to coagulative necrosis (asterisk), showing the same pattern of ablation cavity and surrounding rims as previously described, with progressive decrease in enhancement over time. A thin inner rim of low T2 signal, corresponding to hemosiderin rim (hemorrhagic congestion), can be better identified on the T2 gradient echo sequence (arrowheads—zoomed image). A thick outer rim of intermediate/low T2 signal and post-contrast enhancement (arrows) corresponds to granulation tissue/vascular fibrosis. In subsequent follow-ups, complete resolution of the lesion was observed, with only minor residual fibro-cicatricial changes.

Figure 5.

Figure 5

A 33-year-old man. Axial T1 imaging of a subcutaneous desmoid tumor in the left gluteal region, at different time frames (a: pre-treatment; b: 6 months; c: 11 months; d: 17 months; e: 25 months). In the 6-month post-procedure images, note the ablation cavity encompassing the entire lesion, with a high T1 signal indicative of coagulative necrosis (asterisk). In this case, it is surrounded by an outer rim of intermediate T1 signal (arrow), corresponding to granulation tissue/vascular fibrosis, and an inner rim of fat tissue (arrowhead). In subsequent follow-ups, a better definition of the outer rim of granulation tissue/vascular fibrosis and a reduction in the dimensions of the ablation cavity are evident; these are progressively replaced by adipose tissue.

Table 2. Key magnetic resonance imaging findings after cryoablation of desmoid tumors.

Imaging feature

Definition/description

Non-enhancing ablation cavity

Central zone without enhancement, corresponding to coagulative necrosis

Hemosiderin rim

Thin inner rim of low T2 signal due to hemorrhagic congestion

Granulation tissue/vascular fibrosis

Outer rim with intermediate/high T2 signal and post-contrast enhancement

Progressive fibrosis

Reduction in T2 signal and enhancement over time

Nodular enhancement

New or growing enhancing nodule at cavity margin, suspicious for recurrence

The success rate of cryoablation is directly related to the ice ball encompassing the entire lesion during the procedure. However, cryoablation may induce the “abscopal effect,” leading to the reduction or disappearance of the tumor in non-frozen sites, possibly due to immune modulation (Figure 6). This phenomenon is of high importance in tumor therapy, as it effectively reduces the likelihood of tumor recurrence.15

Figure 6.

Figure 6

A 50-year-old woman. Axial T2 fat-sat (b, c, d, e) and post-contrast axial T1 with and without fat-sat imaging (f-i) have revealed a large, infiltrative desmoid tumor affecting the musculature and subcutaneous tissue of the left scapular region, noted for its progressive growth in control studies over the past 2 years. A computed tomography scan, performed immediately after the removal of the cryoprobes (a), displays the ice ball covering portions of the tumor. Images (b) and (f) show the pre-treatment images. At the 3-month post-procedure follow-up (c, g), a non-enhancing ablation cavity (asterisk) with high T2 signal was noted, indicative of coagulative necrosis, and a significant volume of tumor not included in the ablation zone. By the 10- (d, h) and 18-month (e, i) follow-ups, there was a notable reduction in the overall size of the lesion, including areas that were not directly ablated, possibly due to an abscopal effect of the cryoablation.

Diffusion-weighted imaging (DWI) correlates with the content of the treated tissue, showing higher apparent diffusion coefficient (ADC) values in cases of low cellularity and fibrous content. It can also be used to detect changes in the treated tissue post-cryotherapy. A recent article16 reported low ADC values (mean 0.90 × 10³ mm2/s) in early follow-up of treated tissue after cryotherapy, possibly due to tumor necrosis. This should not be confused with recurrence, especially when no enhancement is present. Further studies are needed to confirm DWI patterns in treated tissue post-cryotherapy. However, this pattern was also observed in some cases in this study, as shown in Figure 7.

Figure 7.

Figure 7

A 33-year-old woman. Axial diffusion-weighted imaging (a, d), apparent diffusion coefficient (ADC) maps (b, e), and post-contrast subtraction images (c, f) of a desmoid tumor in the calf in different time frames post-cryoablation (a-c: 3 months; d-f: 6 months). In early follow-up after cryotherapy, there may be areas of low ADC values, possibly due to tumor necrosis (yellow arrows in a and b; mean 0.8 × 10-³ mm²/s), which should not be confused with recurrence, especially when no enhancement is present. The observed peripheral enhancement (white arrows in c and f) corresponds to granulation tissue/vascular fibrosis. In the follow-up control, an increase in ADC values is observed (asterisk in e; mean 2.8 × 10-³ mm²/s).

Discussion

The management of DTs has become increasingly individualized, tailored around patients’ needs and lesions’ features. Aggressive surgical approaches are generally avoided in favor of more conservative, minimally invasive strategies.17 The current consensus has shifted towards a “watch-and-wait” first-line approach, and intervention is performed for progressive or symptomatic cases.11, 17 In this context, image-guided percutaneous cryoablation has emerged as a valuable and minimally invasive alternative to surgery and systemic therapy.18

Recent studies have shown encouraging outcomes in terms of local control and symptom relief, especially when complete tumor coverage is achieved during ablation.19 This, combined with minimal side effects, has led to its inclusion in recent international guidelines.11, 17, 18, 19 Furthermore, the potential for cryoablation to induce systemic antitumor effects—the so-called abscopal effect—suggests opportunities for synergy with systemic therapies, including immunotherapy.20

Despite these advancements, standardized radiologic criteria for treatment response remain lacking. MRI features, such as transient T2 hyperintensity or DWI changes, may mimic recurrence, especially in early follow-up, if not properly contextualized.21

A deeper understanding of the temporal evolution of these features is essential to avoid misinterpretation and guide clinical decision-making.

Emerging technologies, including artificial intelligence and radiomics, may offer tools to differentiate residual tumor from post-ablation changes. Recent studies have shown that deep learning applied to baseline MRI can predict clinical progression of DTs with high accuracy (up to 93%), suggesting a potential role for artificial intelligence-based tools in risk stratification and treatment planning.22 Finally, growing interest in cryoablation’s immunomodulatory potential may support future therapeutic combinations that enhance outcomes in patients with DTs.

In conclusion, our understanding of DTs is evolving rapidly. MRI plays a central role in evaluating post-cryoablation changes and guiding patient management. DTs treated with percutaneous cryoablation exhibit a predictable sequence of imaging changes over time. Key post-treatment MRI findings include a central non-enhancing cavity of coagulative necrosis, peripheral granulation tissue with enhancement, and progressive fibrosis characterized by decreasing T2 signal and enhancement. Accurate recognition of these patterns is critical to distinguish treatment response from recurrence. Familiarity with expected imaging patterns and their timeline can help avoid misdiagnosis of recurrence and optimize treatment strategies. Future research integrating imaging biomarkers, artificial intelligence, and immunologic response will likely further refine our approach to this complex entity.

Footnotes

Conflict of interest disclosure: The authors declared that they have no conflict of interest.

References

  • 1.Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives. Pathologica. 2021;113(2):70–84. doi: 10.32074/1591-951X-213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.WHO Classification of Tumours Editorial Board. WHO Classification of Tumours: Soft Tissue and Bone Tumours. 5 th ed. Vol 3 [Internet]. Lyon: International Agency for Research on Cancer; 2020 [cited 2025 Nov 6]. [Google Scholar]
  • 3.Kasper B, Baumgarten C, Garcia J, Bonvalot S, Haas R, Haller F, Hohenberger P, Penel N, Messiou C, van der Graaf WT, Gronchi A, Desmoid Working Group, et al. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Ann Oncol. 2017;28(10):2399–2408. doi: 10.1093/annonc/mdx323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Gronchi A, Colombo C, Le Péchoux C, Dei Tos AP, Le Cesne A, Marrari A, Penel N, Grignani G, Blay JY, Casali PG, Stoeckle E, Gherlinzoni F, Meeus P, Mussi C, Gouin F, Duffaud F, Fiore M, Bonvalot S, ISG and FSG, et al. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm–a position paper from the Italian and the French Sarcoma Group. Ann Oncol. 2014;25(3):578–583. doi: 10.1093/annonc/mdt485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Desmoid Tumor Working Group. The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer. 2020;127:96–107. doi: 10.1016/j.ejca.2019.11.013. [DOI] [PubMed] [Google Scholar]
  • 6.Papalexis N, Savarese LG, Peta G, Errani C, Tuzzato G, Spinnato P, Ponti F, Miceli M, Facchini G, et al. The new ice age of musculoskeletal intervention: role of percutaneous cryoablation in bone and soft tissue tumors. Curr Oncol. 2023;30(7):6744–6770. doi: 10.3390/curroncol30070495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Auloge P, Garnon J, Robinson JM, Thenint MA, Koch G, Caudrelier J, Weiss J, Cazzato RL, Kurtz JE, Gangi A, et al. Percutaneous cryoablation for advanced and refractory extra-abdominal desmoid tumors. Int J Clin Oncol. 2021;26(6):1147–1158. doi: 10.1007/s10147-021-01887-y. [DOI] [PubMed] [Google Scholar]
  • 8.Yan YY, Walsh JP, Munk PL, Mallinson PI, Simmons C, Clarkson PW, Jayaram PR, Heran MKS, Ouellette HA, et al. A single-center 10-year retrospective analysis of cryoablation for the management of desmoid tumors. J Vasc Interv Radiol. 2021;32(9):1277–1287. doi: 10.1016/j.jvir.2021.05.025. [DOI] [PubMed] [Google Scholar]
  • 9.Efrima B, Ovadia J, Drukman I, Khoury A, Rath E, Dadia S, Gortzak Y, Albagli A, Sternheim A, Segal O, et al. Cryo-surgery for symptomatic extra-abdominal desmoids. A proof of concept study. J Surg Oncol. 2021;124(4):627–634. doi: 10.1002/jso.26528. [DOI] [PubMed] [Google Scholar]
  • 10.Saltiel S, Bize PE, Goetti P, Gallusser N, Cherix S, Denys A, Becce F, Tsoumakidou G, et al. Cryoablation of extra-abdominal desmoid tumors: a single-center experience with literature review. Diagnostics (Basel) 2020;10(8):556. doi: 10.3390/diagnostics10080556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Kurtz JE, Buy X, Deschamps F, Sauleau E, Bouhamama A, Toulmonde M, Honoré C, Bertucci F, Brahmi M, Chevreau C, Duffaud F, Gantzer J, Garnon J, Blay JY, Gangi A, et al. CRYODESMO-O1: a prospective, open phase II study of cryoablation in desmoid tumour patients progressing after medical treatment. Eur J Cancer. 2021;143:78–87. doi: 10.1016/j.ejca.2020.10.035. [DOI] [PubMed] [Google Scholar]
  • 12.Bouhamama A, Lame F, Mastier C, Cuinet M, Thibaut A, Beji H, Ricoeur A, Blay JY, Pilleul F, et al. Local control and analgesic efficacy of percutaneous cryoablation for desmoid tumors. Cardiovasc Intervent Radiol. 2020;43(1):110–119. doi: 10.1007/s00270-019-02323-5. [DOI] [PubMed] [Google Scholar]
  • 13.Shinagare AB, Ramaiya NH, Jagannathan JP, Krajewski KM, Giardino AA, Butrynski JE, Raut CP, et al. A to Z of desmoid tumors. AJR Am J Roentgenol. 2011;197(6):W1008–1014. doi: 10.2214/AJR.11.6657. [DOI] [PubMed] [Google Scholar]
  • 14.Ganeshan D, Amini B, Nikolaidis P, Assing M, Vikram R. Current update on desmoid fibromatosis. J Comput Assist Tomogr. 2019;43(1):29–38. doi: 10.1097/RCT.0000000000000790. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Okuda M, Yoshida K, Kobayashi S, Gabata T. Desmoid-type fibromatosis: imaging features and course. Skeletal Radiol. 2023;52(7):1293–1303. doi: 10.1007/s00256-023-04275-x. [DOI] [PubMed] [Google Scholar]
  • 16.Chen J, Qian W, Mu F, Niu L, Du D, Xu K. The future of cryoablation: an abscopal effect. Cryobiology. 2020;97:1–4. doi: 10.1016/j.cryobiol.2020.02.010. [DOI] [PubMed] [Google Scholar]
  • 17.Garnon J, Cazzato RL, Autrusseau PA, Koch G, Weiss J, Gantzer J, Kurtz JE, Gangi A, et al. Desmoid fibromatosis: interventional radiology (sometimes) to the rescue for an atypical disease. Br J Radiol. 2025;98(1170):840–850. doi: 10.1093/bjr/tqae128. [DOI] [PubMed] [Google Scholar]
  • 18.Cazzato RL, Gantzer J, de Marini P, Garnon J, Koch G, Buy X, Autrusseau PA, Auloge P, Dalili D, Kurtz JE, Gangi A, et al. Sporadic desmoid tumours: systematic review with reflection on the role of cryoablation. Cardiovasc Intervent Radiol. 2022;45(5):613–621. doi: 10.1007/s00270-022-03091-5. [DOI] [PubMed] [Google Scholar]
  • 19.Kasper B, Baldini EH, Bonvalot S, Callegaro D, Cardona K, Colombo C, Corradini N, Crago AM, Dei Tos AP, Dileo P, Elnekave E, Erinjeri JP, Navid F, Farma JM, Ferrari A, Fiore M, Gladdy RA, Gounder M, Haas RL, Husson O, Kurtz JE, Lazar AJ, Orbach D, Penel N, Ratan R, Raut CP, Roland CL, Schut AW, Sparber-Sauer M, Strauss DC, Van der Graaf WTA, Vitellaro M, Weiss AR, Gronchi A, Desmoid Tumor Working Group, et al. Current management of desmoid tumors: a review. JAMA Oncol. 2024;10(8):1121–1128. doi: 10.1001/jamaoncol.2024.1805. [DOI] [PubMed] [Google Scholar]
  • 20.Yang X, Gao X, Xu C, Ni T, Sheng Y, Wang J, Sun X, Yuan J, Zhang L, Wang Y, et al. Cryoablation synergizes with anti-PD-1 immunotherapy induces an effective abscopal effect in murine model of cervical cancer. Transl Oncol. 2025;51:102175. doi: 10.1016/j.tranon.2024.102175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Düx DM, Chodakiewitz Y, Bitton R, Sewell S, Sheth VR, Ghanouni P, Brunsing RL, et al. MRI features that predict progression of residual disease after ablation of extra-abdominal desmoid fibromatosis. Eur Radiol. 2025;35(7):4161–4170. doi: 10.1007/s00330-024-11319-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Fares R, Atlan LD, Druckmann I, Factor S, Gortzak Y, Segal O, Artzi M, Sternheim A, et al. Imaging-based deep learning for predicting desmoid tumor progression. J Imaging. 2024;10(5):122. doi: 10.3390/jimaging10050122. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Diagnostic and Interventional Radiology are provided here courtesy of Turkish Society of Radiology

RESOURCES